Table 1.

Licensed vascular endothelial growth factor inhibitors reported to affect coexisting psoriasis during treatment of malignancy

Year	Reference	Author	Drug	Mechanism of action	Indication for treatment	Preceding duration of psoriasis (years)	Effect of treatment on coexisting psoriasis	Duration of effect
2007	22	Keshtgapour et al	Sunitinib (SU-011248)	Receptor tyrosine kinase inhibitor	Metastatic renal cell carcinoma	20	“Virtual clearance”	Throughout treatment with cyclical exacerbations
2009	21	Akman et al	Bevacizumab	Anti-VEGF monoclonal antibody	Metastatic colon carcinoma	40	Reduction in PASI from 16.8 to 1.4	At least 3 months (duration of follow-up)
2010	23	Fournier et al	Sorafenib	Multikinase inhibitor	Metastatic renal clear cell carcinoma	56	Clearance of longstanding plaques	4 months until change of treatment
2010	24	Narayanan et al	Sunitinib	Receptor tyrosine kinase inhibitor	Metastatic renal cell carcinoma	5	“Significant improvement”	3.5 years; ongoing therapy with cyclical exacerbations

Note: Copyright © 2011, Informa. Adapted with permission from Crawshaw AA, Griffiths CEM, Young HS. Investigational VEGF antagonists for psoriasis. Expert Opin Invest Drugs. 2012; 21:33–43.¹¹⁴

Abbreviations: PASI, psoriasis area and severity index; VEGF, vascular endothelial growth factor.